Top Markets
#1 DogBull DogBull +49.01%
#2 Siren Siren +29.76%
#3 OriginTrail OriginTrail +21.49%
#4 MarsCoin MarsCoin +14.53%
#5 Verus Coin Verus Coin +7.09%
#6 Xphere Xphere +5.99%
#7 COTI COTI +5.94%
#8 PulseChain PulseChain +5.89%
#9 Concordium Concordium +5.86%
#10 Pons Pons +5.55%
Coin of the day
DogBull DogBull
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Wuhan YZY Biopharma Co Ltd Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd

2496
Rang in Aktien #22213
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the... Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Aktienkurs
$0.46053443
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$92.44M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-36.86%
Land
CN
Handel Wuhan YZY Biopharma Co Ltd (2496)

Kategorie

Healthcare
P/B-Verhältnis für Wuhan YZY Biopharma Co Ltd (2496)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Wuhan YZY Biopharma Co Ltd beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Wuhan YZY Biopharma Co Ltd von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH